VEGFA vascular endothelial growth factor A
ENSG00000112715 · protein coding · Open Targets profile
[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia- mediated cell death (By similarity). {ECO:0000250|UniProtKB:Q00731, ECO:0000269|PubMed:35455969}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Med-Quality Pocket
- Antibody
- Approved Drug, UniProt loc high conf, GO CC high conf, UniProt loc med conf
- PROTAC
- Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.402319997549057 (upper bound 0.5846199989318848). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 301 registry trials, updated in the last three years, of the most advanced drugs against VEGFA (abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Pablo Velazquez-MartinKodiak Sciences Inc · 6 of 6 trials Phase 2+Ph3NCT06556368 · A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKbrief
- Adam TurpcuAdverum Biotechnologies, Inc. · 4 of 4 trials Phase 2+Ph2NCT05536973 · Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]brief
- Charles MillerEyeBiotech Ltd. · 3 of 3 trials Phase 2+
- Hong DaiBeijing Hospital · 2 of 2 trials Phase 2+
- Jennifer M KissnerOutlook Therapeutics, Inc. · 2 of 2 trials Phase 2+
- Mark NelsonWake Forest University Health Sciences · 2 of 2 trials Phase 2+
- Sotaro TakigawaKyowa Kirin Co., Ltd. · 2 of 2 trials Phase 2+
- Timothy L JacksonKings College London & Kings College Hospital · 2 of 2 trials Phase 2+
- Youxin ChenPeking Union Medical College · 2 of 2 trials Phase 2+
- Adam RothmanUniversity of Miami · 1 of 1 trials Phase 2+
- Ahmad TarhiniMoffitt Cancer Center · 1 of 1 trials Phase 2+
- Amira A. NayelClinical researcher and PhD student at the Faculty of Pharmacy, Alexandria University · 1 of 1 trials Phase 2+
- Anat LoewensteinTel-Aviv Sourasky Medical Center · 1 of 1 trials Phase 2+
- Anders KvantaSt. Erik Eye Hospital · 1 of 1 trials Phase 2+
- Andreas WedrichDepartment of Ophthalmology, Medical University Graz · 1 of 1 trials Phase 2+
Registry trials of abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 195 of 286 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 15 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
137 trials of drugs against VEGFA were stopped early; 28 give no reason
Terminated, withdrawn and suspended interventional trials of abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 137.
- terminated · 2026-10-20 · Massachusetts Eye and Ear Infirmary · Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept“Funding prematurely ended”
- terminated · 2026-01-26 · Centre Hospitalier Universitaire Dijon · Aflibercept Injection [Eylea]“very rare disease, many difficulties in recruiting patients, inclusion rate far too slow, making it impossible to meet the main objective within a reasonable timeframe. the sponsor therefore decided to stop the study.”
- terminated · 2025-09-24 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Ziv-Aflibercept“Slow accrual”
- terminated · 2025-08-05 · Opthea Limited · 2.0 aflibercept“The primary endpoint was not achieved in the study.”
- terminated · 2025-07-22 · Opthea Limited · 0.5 mg ranibizumab“The primary endpoint was not achieved in the study.”
- terminated · 2025-03-13 · IVERIC bio, Inc. · matched by the registry's drug synonyms“Following Sponsor reassessment, OPH2004 enrollment was stopped to initiate a new Zimura wet AMD trial, OPH2007, for treatment-naïve patients. Thus, only one patient was enrolled into and completed Study OPH2004.”
- terminated · 2025-02-24 · Wake Forest University Health Sciences · Aflibercept Ophthalmic“IRB stopped study due to safety concerns. No further data collection and what has been collected is not appropriate for analysis.”
- terminated · 2024-10-31 · Ophthotech Corporation · bevacizumab or afliberceptNo reason given
- terminated · 2024-10-30 · Ophthotech Corporation · ranibizumab, afliberceptNo reason given
- terminated · 2024-10-30 · Ophthotech Corporation · ranibizumabNo reason given
- terminated · 2024-10-30 · Ophthotech Corporation · ranibizumabNo reason given
- terminated · 2024-10-16 · Bayer · Aflibercept(BAY86-5321, Eylea)“Study terminated due to administrative reasons not related to efficacy or safety.”
- terminated · 2024-10-15 · Tufts Medical Center · Aflibercept“Low enrollment”
- terminated · 2024-08-22 · Kodiak Sciences Inc · Aflibercept“Study did not meet primary endpoint”
- terminated · 2024-08-22 · Kodiak Sciences Inc · Aflibercept“Study did not meet primary endpoint”
- terminated · 2024-07-18 · Kodiak Sciences Inc · Aflibercept“Primary Endpoint Not Met”
- withdrawn · 2024-05-30 · Asociación para Evitar la Ceguera en México · intravitreal injection of ranibizumab“Undefined”
- withdrawn · 2024-03-22 · Wake Forest University Health Sciences · Ranibizumab“IRB stopped study due to safety concerns before any participants were enrolled.”
- terminated · 2024-02-23 · Ophthotech Corporation · matched by the registry's drug synonymsNo reason given
- withdrawn · 2024-02-21 · Ophthotech Corporation · matched by the registry's drug synonyms“No patients were enrolled. Study terminated for portfolio reasons.”
- withdrawn · 2024-01-18 · Hoffmann-La Roche · Ranibizumab, Aflibercept“Roche/Genentech has initiated an immediate pause of all new PDS implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use”
- withdrawn · 2023-10-02 · Imperial College London · Ranibizumab Injection [Lucentis]“Funder withdrawn funding.”
- terminated · 2023-08-18 · Oxurion · Aflibercept“Based on data obtained in Part A, there was insufficient evidence of efficacy on the key outcome measures. As a result, the study was not advanced to Part B.”
- withdrawn · 2023-08-15 · University of Nebraska · Ranibizumab“Funding lost and study never started”
- terminated · 2023-08-14 · PolyPhotonix Medical · Ranibizumab“Major protocol deviations compromised the study.”
Paediatric incentives and obligations for VEGFA's drugs
For abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · VEGFA is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002817-PIP05-23 (Faricimab, Treatment of choroidal neovascularisation secondary to pathologic myopia): W: decision granting a waiver in all age groups for all conditions or indications, 12 Jan 2024; EMEA-000236-PIP05-18 (aflibercept, Treatment of retinopathy of prematurity): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 4 Apr 2019; compliance positive 15 Oct 2021; EMEA-002691-PIP02-20 (Brolucizumab, Treatment of diabetic retinopathy): W: decision granting a waiver in all age groups for all conditions or indications, 23 Oct 2020; EMEA-002832-PIP01-20 (ranibizumab, Treatment of diabetic retinopathy): W: decision granting a waiver in all age groups for all conditions or indications, 9 Sept 2020; +10 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Eydenzelt: authorised since 12 Feb 2025; Ahzantive: authorised since 13 Jan 2025; Baiama: authorised since 13 Jan 2025; Vabysmo: authorised since 15 Sept 2022; +26 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 56 interventional studies of abicipar pegol, faricimab, ranibizumab, aflibercept, brolucizumab, pegaptanib octasodium, muparfostat, bevasiranib, conbercept, vanucizumab include patients under 18; 6 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 13 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.